Principal Investigator
Macarena De La Fuente
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250433
Clinical Trial Summary
A Phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1 (IDH1)-mutant glioma
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Neurological Cancer
Contact Information
Phone Number
305-243-2647